ATN
ATN is the Sydney flagship television station of the Seven Network in Australia. The licence, issued to a company named Amalgamated Television Services, a subsidiary of Fairfax, was one of the first four licences (two in Sydney, two in Melbourne) to be issued for commercial television stations in Australia. It began broadcasting on 2 December 1956.
The station formed an affiliation with GTV-9 Melbourne in 1957, in order to share content. In 1963, Frank Packer ended up owning both GTV-9 and TCN-9, so as a result the stations switched their previous affiliations. ATN-7 and HSV-7 joined to create the Australian Television Network, which later became the Seven Network. ATN-7 is the home of the national level Seven News bulletins.
The studios and transmission tower
The station opened in 1956 with principal offices and studios located at Mobbs Lane, Epping (a suburb about 18 kilometres north west of Sydney). The initial black and white cameras and other equipment was supplied by the Marconi Company of England. Conversion to PAL colour occurred on 1 March 1975. Digital DVB-T commenced on 1 January 2001.
ATN1
Atrophin-1 is a protein that in humans is encoded by the ATN1 gene. It is expressed in nervous tissue.
Function
Dentatorubral pallidoluysian atrophy is a rare neurodegenerative disorder characterized by cerebellar ataxia, myoclonic epilepsy, choreoathetosis, and dementia. The disorder is related to the expansion of a trinucleotide repeat within this gene. The encoded protein includes a serine repeat and a region of alternating acidic and basic amino acids, as well as the variable glutamine repeat. Alternative splicing results in two transcripts variants that encode the same protein.
Clinical significance
Mutations in ATN1 are associated with a form of trinucleotide repeat disorder known as "dentatorubral-pallidoluysian atrophy" or "dentatorubropallidoluysian atrophy".
Interactions
ATN1 has been shown to interact with:
References
Further reading
External links
Bis-choline tetrathiomolybdate
Bis-choline tetrathiomolybdate, or WTX101, is a salt of tetrathiomolybdate (TTM, MoS42−) and choline currently under investigation as a therapy against Wilson's disease, a rare and potentially fatal disease in which the body cannot regulate copper. Wilson disease is an autosomal recessive genetic disorder that is manifested by serious hepatic, neurologic or psychiatric symptoms. The disease is fatal if left undiagnosed and untreated. It is estimated that approximately 1 individual in every 15,000 worldwide have Wilson's disease, corresponding to approximately 30,000 individuals in the European Union and approximately 20,000 in the United States.
Bis-choline tetrathiomolybdate has been evaluated in clinical trials in patients with various forms of cancer and has received orphan designation in the US and EU as a potential therapy against Wilson disease.
Bis-choline salt of tetrathiomolybdate is a de-coppering therapy in clinical development against Wilson disease under the code name WTX101 by Wilson Therapeutics AB. Wilson Therapeutics was founded by HealthCap in 2012.
